Modeling Common and Rare Genetic Risk Factors of Neuropsychiatric Disorders in Human Induced Pluripotent Stem Cells

Overview

Journal Schizophr Res

Specialty Psychiatry

Date 2022 Apr 23

PMID 35459617

Authors

Abdurrahman W Muhtaseb

Jubao Duan

Affiliations

Soon will be listed here.

Abstract

Recent genome-wide association studies (GWAS) and whole-exome sequencing of neuropsychiatric disorders, especially schizophrenia, have identified a plethora of common and rare disease risk variants/genes. Translating the mounting human genetic discoveries into novel disease biology and more tailored clinical treatments is tied to our ability to causally connect genetic risk variants to molecular and cellular phenotypes. When combined with the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) nuclease-mediated genome editing system, human induced pluripotent stem cell (hiPSC)-derived neural cultures (both 2D and 3D organoids) provide a promising tractable cellular model for bridging the gap between genetic findings and disease biology. In this review, we first conceptualize the advances in understanding the disease polygenicity and convergence from the past decade of iPSC modeling of different types of genetic risk factors of neuropsychiatric disorders. We then discuss the major cell types and cellular phenotypes that are most relevant to neuropsychiatric disorders in iPSC modeling. Finally, we critically review the limitations of iPSC modeling of neuropsychiatric disorders and outline the need for implementing and developing novel methods to scale up the number of iPSC lines and disease risk variants in a systematic manner. Sufficiently scaled-up iPSC modeling and a better functional interpretation of genetic risk variants, in combination with cutting-edge CRISPR/Cas9 gene editing and single-cell multi-omics methods, will enable the field to identify the specific and convergent molecular and cellular phenotypes in precision for neuropsychiatric disorders.

Citing Articles

Scaled and efficient derivation of loss-of-function alleles in risk genes for neurodevelopmental and psychiatric disorders in human iPSCs.

Zhang H, McCarroll A, Peyton L, Diaz de Leon-Guerrerro S, Zhang S, Gowda P Stem Cell Reports. 2024; 19(10):1489-1504.

PMID: 39270650 PMC: 11561461. DOI: 10.1016/j.stemcr.2024.08.003.

Harnessing stem cell-based approaches for clinically meaningful discoveries in schizophrenia.

Lizano P, Karmacharya R Schizophr Res. 2024; 273:1-3.

PMID: 39209607 PMC: 11570341. DOI: 10.1016/j.schres.2024.08.006.

Scaled and Efficient Derivation of Loss of Function Alleles in Risk Genes for Neurodevelopmental and Psychiatric Disorders in Human iPSC.

Zhang H, Peyton L, McCarroll A, de Leon Guerrerro S, Zhang S, Gowda P bioRxiv. 2024; .

PMID: 38562852 PMC: 10983959. DOI: 10.1101/2024.03.18.585542.

Human stem cell modeling of neuropsychiatric disorders: from polygenicity to convergence.

Duan J Med Rev (2021). 2024; 3(4):347-350.

PMID: 38235404 PMC: 10790208. DOI: 10.1515/mr-2023-0016.

Brain Lipids and Lipid Droplet Dysregulation in Alzheimer's Disease and Neuropsychiatric Disorders.

Zhao X, Zhang S, Sanders A, Duan J Complex Psychiatry. 2023; 9(1-4):154-171.

PMID: 38058955 PMC: 10697751. DOI: 10.1159/000535131.

References

Sacai H, Sakoori K, Konno K, Nagahama K, Suzuki H, Watanabe T . Autism spectrum disorder-like behavior caused by reduced excitatory synaptic transmission in pyramidal neurons of mouse prefrontal cortex. Nat Commun. 2020; 11(1):5140. PMC: 7552417. DOI: 10.1038/s41467-020-18861-3. View

Hess J, Tylee D, Mattheisen M, Borglum A, Als T, Grove J . A polygenic resilience score moderates the genetic risk for schizophrenia. Mol Psychiatry. 2019; 26(3):800-815. PMC: 7058518. DOI: 10.1038/s41380-019-0463-8. View

Avazzadeh S, Quinlan L, Reilly J, McDonagh K, Jalali A, Wang Y . NRXN1α is associated with increased excitability in ASD iPSC-derived neurons. BMC Neurosci. 2021; 22(1):56. PMC: 8442436. DOI: 10.1186/s12868-021-00661-0. View

Panchision D . Concise Review: Progress and Challenges in Using Human Stem Cells for Biological and Therapeutics Discovery: Neuropsychiatric Disorders. Stem Cells. 2016; 34(3):523-36. PMC: 4803616. DOI: 10.1002/stem.2295. View

Flaherty E, Zhu S, Barretto N, Cheng E, Deans P, Fernando M . Neuronal impact of patient-specific aberrant NRXN1α splicing. Nat Genet. 2019; 51(12):1679-1690. PMC: 7451045. DOI: 10.1038/s41588-019-0539-z. View

Alexander Arguello P, Addington A, Borja S, Brady L, Dutka T, Gitik M . From genetics to biology: advancing mental health research in the Genomics ERA. Mol Psychiatry. 2019; 24(11):1576-1582. DOI: 10.1038/s41380-019-0445-x. View

Hook V, Brennand K, Kim Y, Toneff T, Funkelstein L, Lee K . Human iPSC neurons display activity-dependent neurotransmitter secretion: aberrant catecholamine levels in schizophrenia neurons. Stem Cell Reports. 2014; 3(4):531-8. PMC: 4223699. DOI: 10.1016/j.stemcr.2014.08.001. View

de Vrij F, Bouwkamp C, Gunhanlar N, Shpak G, Lendemeijer B, Baghdadi M . Candidate CSPG4 mutations and induced pluripotent stem cell modeling implicate oligodendrocyte progenitor cell dysfunction in familial schizophrenia. Mol Psychiatry. 2018; 24(5):757-771. PMC: 6755981. DOI: 10.1038/s41380-017-0004-2. View

Cadwell C, Scala F, Li S, Livrizzi G, Shen S, Sandberg R . Multimodal profiling of single-cell morphology, electrophysiology, and gene expression using Patch-seq. Nat Protoc. 2017; 12(12):2531-2553. PMC: 6422019. DOI: 10.1038/nprot.2017.120. View

10.

Wu J, Kosten T, Zhang X . Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 46:200-6. DOI: 10.1016/j.pnpbp.2013.02.015. View

11.

Page S, Sripathy S, Farinelli F, Ye Z, Wang Y, Hiler D . Electrophysiological measures from human iPSC-derived neurons are associated with schizophrenia clinical status and predict individual cognitive performance. Proc Natl Acad Sci U S A. 2022; 119(3). PMC: 8784142. DOI: 10.1073/pnas.2109395119. View

12.

Szatkiewicz J, ODushlaine C, Chen G, Chambert K, Moran J, Neale B . Copy number variation in schizophrenia in Sweden. Mol Psychiatry. 2014; 19(7):762-73. PMC: 4271733. DOI: 10.1038/mp.2014.40. View

13.

Calderon D, Nguyen M, Mezger A, Kathiria A, Muller F, Nguyen V . Landscape of stimulation-responsive chromatin across diverse human immune cells. Nat Genet. 2019; 51(10):1494-1505. PMC: 6858557. DOI: 10.1038/s41588-019-0505-9. View

14.

Stefansson H, Ophoff R, Steinberg S, Andreassen O, Cichon S, Rujescu D . Common variants conferring risk of schizophrenia. Nature. 2009; 460(7256):744-7. PMC: 3077530. DOI: 10.1038/nature08186. View

15.

Xu P, Liu Z, Liu Y, Ma H, Xu Y, Bao Y . Genome-wide interrogation of gene functions through base editor screens empowered by barcoded sgRNAs. Nat Biotechnol. 2021; 39(11):1403-1413. DOI: 10.1038/s41587-021-00944-1. View

16.

Marshall C, Howrigan D, Merico D, Thiruvahindrapuram B, Wu W, Greer D . Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nat Genet. 2016; 49(1):27-35. PMC: 5737772. DOI: 10.1038/ng.3725. View

17.

Mok B, de Moraes M, Zeng J, Bosch D, Kotrys A, Raguram A . A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature. 2020; 583(7817):631-637. PMC: 7381381. DOI: 10.1038/s41586-020-2477-4. View

18.

Pasca A, Sloan S, Clarke L, Tian Y, Makinson C, Huber N . Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture. Nat Methods. 2015; 12(7):671-8. PMC: 4489980. DOI: 10.1038/nmeth.3415. View

19.

Khattak S, Brimble E, Zhang W, Zaslavsky K, Strong E, Ross P . Human induced pluripotent stem cell derived neurons as a model for Williams-Beuren syndrome. Mol Brain. 2015; 8(1):77. PMC: 4657290. DOI: 10.1186/s13041-015-0168-0. View

20.

Yao Y, Guo W, Zhang S, Yu H, Yan H, Zhang H . Cell type-specific and cross-population polygenic risk score analyses of gene pathway in schizophrenia. iScience. 2021; 24(7):102785. PMC: 8283158. DOI: 10.1016/j.isci.2021.102785. View